Clinical Pathways Platform Adds New Disease States Via Expanded NCCN Partnership


McKesson Specialty Health and The US Oncology Network have expanded their agreement with the National Comprehensive Cancer Network (NCCN) to add five new disease states to Value Pathways.


Related Content

NCCN releases guidelines for myelofibrosis

Bevacizumab added to NCCN recommendations for mesothelioma


Value Pathways are evidenced-based treatment recommendations for oncology supported by NCCN delivered through McKesson Specialty Health’s clinical quality and regimen support system – Clear Value Plus. This point-of-care resource now offers recommendations regarding 27 different disease states, including the new additions of bladder cancer, esophageal cancer, gastric cancer, kidney cancer, and myelodysplastic syndromes.

The agreement between NCCN and McKesson Specialty Health also calls for 15 additional disease states within the next three years, ensuring providers that use Clear Value Plus will have access to latest information on cancer research.

“NCCN is pleased to expand our collaboration with McKesson Specialty Health and further enhance Value Pathways powered by NCCN,” said Robert W Carlson, MD, chief executive officer, NCCN, in a press release (June 14, 2017). “In supporting this expanded agreement, both NCCN and McKesson recognize the value of having evidence-based NCCN Guidelines recommendations at the point of care facilitated through technology to achieve the best outcomes for patients with cancer.”

Along with tracking clinical pathway adherence, Clear Value Plus supports value-based care by including financial information, benchmarking, and providing timely reporting on performance metrics. Additionally, financial transparency between Value Pathways and Clear Value Plus promotes evaluation of cost-effectiveness of different cancer treatment regimens with similar survival outcomes.

“Value Pathways powered by NCCN and Clear Value Plus enable us to deliver high-quality, evidence-based care that gives our patients the best chance for a positive result and a good quality of life while providing high value to both patients and payers,” said Debra Patt, MD, MPH, MBA, vice president of Public Policy and Academic Affairs for Texas Oncology, an affiliate of The US Oncology Network.—Zachary Bessette